Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial

BACKGROUND: Vorapaxar, a protease‐activated receptor‐1 antagonist, is approved for secondary prevention of cardiovascular events but is associated with increased intracranial hemorrhage. METHODS AND RESULTS: TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales: Ungar, Leo, Clare, Robert M., Rodriguez, Fatima, Kolls, Bradley J., Armstrong, Paul W., Aylward, Philip, Held, Claes, Moliterno, David J., Strony, John, Van de Werf, Frans, Wallentin, Lars, White, Harvey D., Tricoci, Pierluigi, Harrington, Robert A., Mahaffey, Kenneth W., Melloni, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405615/
https://www.ncbi.nlm.nih.gov/pubmed/30526198
http://dx.doi.org/10.1161/JAHA.118.009609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405615/
https://www.ncbi.nlm.nih.gov/pubmed/30526198
http://dx.doi.org/10.1161/JAHA.118.009609

Ejemplares similares